MedTrace Logo

The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension

NCT03273387 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2019-10-03

Study results available
· View outcomes & findings →

Summary

The study will evaluate the effect of trimetazidine versus placebo in addition to standard pulmonary arterial hypertension regime on right ventricular function in pulmonary arterial hypertension patients.

Conditions

  • Precapillary Pulmonary Hypertension

Interventions

DRUG

Trimetazidine

The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.

DRUG

Placebo oral capsule

The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.

Sponsors & Collaborators

  • Indonesia University

    lead OTHER

Principal Investigators

  • Hary Sakti Muliawan, MD,PhD · Department Cardiology and Vascular Medicine Universitas Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-10
Primary Completion
2018-11-01
Completion
2018-12-14

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03273387 on ClinicalTrials.gov